Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-06-11Clinical Trial Update: Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study [Phase 3]
A Phase 3 extension study in Japan for the KEYNOTE-189 regimen evaluating pembrolizumab added to pemetrexed and platinum chemotherapy as fir…
-
CLINICAL_TRIALS trial_result · 2020-06-11Clinical Trial Update: Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating osimertinib with bevacizumab for leptomeningeal metastasis in EGFR-mutant non-small cell lung cancer is in progress…
-
CLINICAL_TRIALS trial_result · 2020-06-11Clinical Trial Update: CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients [Phase 2]
Phase 2 trial investigating CTA expression/methylation and response to pembrolizumab in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2020-06-11Clinical Trial Update: Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC [Phase 2]
Phase 2 trial evaluating camrelizumab combined with apatinib mesylate and standard chemotherapy in ALK-positive advanced non-small cell lung…
-
CLINICAL_TRIALS withdrawal · 2020-06-09Clinical Trial Update: INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) [Phase 3]
Phase 3 trial INCMGA00012 in combination with chemoradiation for stage III non-small cell lung cancer has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-06-09Clinical Trial Update: A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC [Phase 3]
Phase 3 study update evaluating SHR-1210 in combination with pemetrexed and carboplatin for non-squamous non-small cell lung cancer has comp…
-
CLINICAL_TRIALS trial_result · 2020-06-01Clinical Trial Update: Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer [Phase 1, Phase 2]
Clinical trial update on the safety and efficacy of AMG 820 plus pembrolizumab in select advanced solid tumors (Phase 1/2; completed).
-
CLINICAL_TRIALS trial_result · 2020-05-28Clinical Trial Update: Vaccine Treatment for Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]
Clinical trial update on a vaccine treatment for advanced non-small cell lung cancer reported as completed in Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2020-05-28Clinical Trial Update: Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer [Phase 2, Phase 3]
Phase 2/3 immunotherapy trial in progressive or relapsed non-small cell lung cancer was terminated.
-
CLINICAL_TRIALS trial_result · 2020-05-27Clinical Trial Update: Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis [Phase 4]
Clinical trial update evaluating recombinant human endostatin for leptomeningeal metastasis in non-small cell lung cancer (Phase 4) with eff…
-
CLINICAL_TRIALS trial_result · 2020-05-27Clinical Trial Update: Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis [Phase 4]
Phase 4 trial update evaluating the efficacy and safety of durvalumab in leptomeningeal metastasis.
-
CLINICAL_TRIALS trial_result · 2020-05-15Clinical Trial Update: Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer [Phase 1]
Phase 1 trial investigating anetumab ravtansine combined with atezolizumab in mesothelin-positive advanced non-small cell lung cancer; study…
-
CLINICAL_TRIALS trial_result · 2020-05-12Clinical Trial Update: Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer [Phase 2]
A Phase 2 trial evaluating docetaxel with or without suramin in second-line advanced non-small cell lung cancer has completed with results p…
-
CLINICAL_TRIALS trial_result · 2020-05-11Clinical Trial Update: Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial update involving Avastin with Docetaxel and Carboplatin for non-small cell lung cancer; study completed with results …
-
FDA approval · 2020-05-08FDA Approved: RETEVMO — Original Application (Eli Lilly and Company)
FDA approved Retevmo (selpercatinib) from Eli Lilly in its original NDA. The approval covers RET fusion-positive non-small cell lung cancer …
-
CLINICAL_TRIALS trial_result · 2020-05-08Clinical Trial Update: Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 3]
A Phase 3 trial evaluating camrelizumab with or without apatinib mesylate as first-line treatment in PD-L1 positive relapsed or advanced non…
-
FDA approval · 2020-05-06FDA Approved: TABRECTA — Original Application (Novartis Pharmaceuticals Corporation)
FDA approved Tabrecta (capmatinib) under Original Application NDA213591 from Novartis for the treatment of adults with metastatic non-small …
-
CLINICAL_TRIALS trial_result · 2020-05-04Clinical Trial Update: Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors [Phase 1]
Phase 1 trial evaluating safety and tolerability of Andecaliximab as monotherapy and in combination with chemotherapy in advanced solid tumo…
-
CLINICAL_TRIALS trial_result · 2020-05-01Clinical Trial Update: Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC [Phase 2]
A Phase 2 clinical trial evaluating sintilimab (IBI308) as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer, with…
-
CLINICAL_TRIALS trial_result · 2020-04-28Clinical Trial Update: A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial investigating atezolizumab as first-line monotherapy for advanced or metastatic non-small cell lung cancer has completed with …
-
CLINICAL_TRIALS trial_result · 2020-04-24Clinical Trial Update: Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery [Phase 1, Phase 2]
Phase 1/2 trial evaluating nelfinavir with radiation, cisplatin, and etoposide in stage III non-small cell lung cancer unsuitable for surger…
-
CLINICAL_TRIALS trial_result · 2020-04-24Clinical Trial Update: Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib [Phase 2]
Phase 2 clinical trial evaluating gefitinib combined with anlotinib in advanced non-squamous non-small cell lung cancer with uncleared plasm…
-
CLINICAL_TRIALS trial_result · 2020-04-22Clinical Trial Update: Nitroglycerin Plus Intracranial Radiotherapy for Brain Metastases in NSCLC Patients [Phase 2]
Phase 2 clinical trial evaluating nitroglycerin plus intracranial radiotherapy versus radiotherapy alone in NSCLC patients with brain metast…
-
CLINICAL_TRIALS trial_result · 2020-04-16Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy [Phase 2]
Phase 2 trial assessing safety and efficacy of ex vivo expanded autologous immune killer cells in stage IV non-small cell lung cancer who fa…
-
FDA approval · 2020-04-16FDA Approved: ERLOTINIB — Original Application (Zydus Lifesciences Limited)
FDA approved a generic erlotinib product from Zydus Lifesciences Limited under an original ANDA submission.